MAR. 10. 2004 12:23PM

EDWARDS IRV DEPT 949 250 6850

NO. 2058 P. 1

Docket No. ECV-5589DIV

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Group Art Unit: 3738 In re application of: Michael Helmus et al. Examiner: Not Assigned Application No.: 10/700,958 Filing Date: October 31, 2003 For: BIOACTIVE COATINGS TO PREVENT TISSUE OVERGROWTH ON ARTIFICIAL HEART VALVES

### REQUEST FOR CORRECTED FILING RECEIPT

Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

Attn: Office of Initial Patent Examination's Filing Receipt Corrections

Dear Sir:

Attached is a copy of the official filing receipt in connection with the above-identified patent application for which issuance of a corrected filing receipt is respectfully requested.

Please correct the Assignee as indicated below:

Incorrect

**Edwards Lifesciences Corporation** Baxter Healthcare Corporation

Correct

Edwards Lifesciences Corporation

<u>VIA FACSIMILE (703) 746-9195</u>

Attached please find a copy of the Notice of Recordation and Assignment recorded in the parent application Serial No. 09/571,987. If any fees are deemed necessary, please charge our Deposit Account No. 50-1225 (Docket No. ECV-5589DIV). Should there be any questions with respect to the abovementioned, please do not hesitate to contact the undersigned.

Date: March 10, 2004

Respectfully submitted,

Rajiv Yada , Reg. No. 43,999

Edwards Lifesciences LLC

Law Department One Edwards Way

Irvine, California 92614

Customer No. 30452

Telephone: (949) 250-6801

CERTIFICATE OF FACSIMILE TRANSMISSION TO THE U.S. PATENT AND TRADEMARK OFFICE

J hereby certify under 37 CFR § 1.8 that the above-identified document is being transmitted via facsimile to the Commissioner of Patents. (703) 746-9195 on March 10, 2004. Atm.: Office of Initial Patent Examination's Filing Recoint Corrections, facultaile of

Aelisso Sancher

1416vl

PAGE 1/8 \* RCVD AT 3/10/2004 3:23:01 PM [Eastern Standard Time] \* SVR:USPTO-EFXRF-2/0 \* DNIS:7469195 \* CSID:949 250 6850 \* DURATION (mm-ss):03-20



#### United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patients and Tradismont Office. Addition Commissioner FOR PATENTS PC. Doc 1479 Absolute, Vigena 1231-1430

					144 000 000			
APPL NO.	FILING OR 371 (c) DATE		FIL FEE REC'D	ATTY.DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS	
10/700,958	10/31/2003	3738	788	ECV-5589 DIV		21	1	

**CONFIRMATION NO. 5993** 

30452 EDWARDS LIFESCIENCES CORPORATION ONE EDWARDS WAY IRVINE, CA 92614

Date Mailed: 02/03/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt, if an error is noted on this Filling Receipt, please write to the Office of Initial Patent Examination's Filling Receipt Corrections, facsimile number 703-748-9195. Please provide a copy of this Filling Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filling Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filling Receipt incorporating the requested corrections (if appropriate).

#### Applicant(s)

Michael N. Helmus, Long Beach, CA; Crystal Cunanan, Mission Viejo, CA; Relph Kafesjlan, Newport Beach, CA; Patrice Tremble, Irvine, CA;

#### Assignment For Published Patent Application

Edwards Lifeschances Corporation, Irvine, CA; Baxter Healthcare Corporation, Irvine, CA;

#### Domestic Priority data as claimed by applicant

This application is a DIV of 09/571,987 05/16/2000 which claims benefit of 60/178,084 01/25/2000

#### **Foreign Applications**

UNITED STATES OF AMERICA PCT/US01/02621 01/25/2001

If Required, Foreign Filing License Granted: 02/02/2004

Projected Publication Date: 05/13/2004

Non-Publication Request: No

Early Publication Request: No

Title

Bloactive coatings to prevent tissue overgrowth on artificial heart valves

**Preliminary Class** 

623

# LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37. Code of Federal Regulations, 5,11 & 5,15

#### GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

#### **NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).